Actively Recruiting

Age: 18Years - 75Years
All Genders
ID04809025

Comparison of Endoscopic Biopsy and Surgical Specimen for Molecular Diagnosis of Gastric Cancer

Led by Fudan University · Updated on 2025-09-29

510

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating whether testing for various molecular and histological features of gastric cancer, such as histological type, grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status, is as reliable on preoperative endoscopic biopsy samples as on surgical resection specimens. This is important because some gastric cancers treated before surgery may show no remaining tumor, making surgical specimens unavailable for testing. Using biopsy specimens could allow earlier genetic information to guide treatment decisions. The study compares the testing results from two sources: endoscopic biopsy specimens obtained before surgery using a gastroscope, and surgical resection specimens collected during radical gastrectomy. Both sets of samples are analyzed for the listed molecular and histological markers. The study is observational and does not involve experimental treatments but monitors and compares diagnostic accuracy and testing completeness from these two specimen types. Participants will undergo endoscopy to collect biopsy samples and then have surgery to remove the tumor for further testing. Researchers will assess the diagnostic accuracy over two years, the proportion of incomplete molecular pathology results, and procedure duration. The study involves informed consent, pathology assessments, and follows participants through the diagnostic process to understand if biopsy samples can reliably replace surgical specimens for molecular diagnosis in gastric cancer.

CONDITIONS

Brief Title

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years old
  • Histologically confirmed primary gastric adenocarcinoma
  • Diagnostic biopsies collected within 12 months prior to enrollment
  • Written informed consent provided
  • Planned for radical R0 gastrectomy surgery
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Patients unable to undergo tumor resection surgery
  • Serious diseases including cardiovascular, respiratory, kidney, liver diseases, uncontrolled hypertension, diabetes, mental disorders
  • Poor compliance or considered unlikely to comply with study requirements
  • Received anticancer drugs, biotherapy, radiotherapy, or immunotherapy within 4 weeks before or after enrollment
  • History of organ transplantation, long-term immunosuppressant use, or autoimmune diseases

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Within 12 months prior to enrollment

Participants undergo endoscopic biopsy to collect tissue samples for molecular testing of gastric cancer.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Single surgical procedure with immediate post-operative care

Participants undergo radical gastrectomy surgery to obtain surgical resection specimens for molecular testing and pathological diagnosis.

1 surgical visit and post-operative hospital stay

Long-term Monitoring

Duration - Up to 2 years

Participants are observed for up to 2 years to assess diagnostic accuracy and completeness of molecular pathology testing.

Periodic visits depending on clinical follow-up schedule

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

Loading map...

Research Team

D

Dazhi Xu, PHD, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase 1b/2 Open-Label Study of Disitamab Vedotin With Tuca...

Breast Neoplasms

Actively Recruiting

141 locations

A Phase 1a/b Open-Label Trial Evaluating LY4257496, a GRPR-T...

Breast Neoplasms

Actively Recruiting

30 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here